Fresenius and WuXi Biologics Partner on Biosimilars Pipeline

The German healthcare group and the Chinese biologics company have entered an exclusive agreement to develop biosimilar drugs.

German healthcare company Fresenius and Chinese firm WuXi Biologics have signed an exclusive development agreement, as reported by MarketScreener and radio station WSAU.

The partnership is aimed at expanding Fresenius's pipeline of biosimilars — medical products designed to be highly similar to existing biological drugs. The collaboration is expected to support development capabilities across both companies in this field.

Financial terms of the agreement, project timelines, and specific drug candidates have not yet been released.